Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer

Nice, Alpes-Maritimes 06189

0 studies enrolling now · 2 studies all time

What they study most

Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, Solid Tumor

Studies at this site

• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types — Recruiting now
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed